Sarepta Therapeutics, Inc. (SRPT) Institutional Ownership

Ownership Summary

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has 339 institutional investors with active 13F positions as of December 2025.

• These investors held 93.4% of outstanding shares in December 2025, down from 157.4% in September 2025.
• They increased total shares held in Sarepta Therapeutics by 9.0% from last quarter, and the number of investors in SRPT decreased 26.14% annually.
• During the quarter, 204 of these 339 funds increased positions in SRPT, 91 reduced exposure, and 44 held steady.
• The aggregate institutional position in Sarepta Therapeutics amounted to 93.65Mn shares as of December 2025, up by 7.74Mn shares quarter on quarter, and up 71.58K shares year over year.
• BlackRock, Inc. leads ownership in SRPT with 14.76Mn shares as of December 31, 2025, equal to 14.72% of outstanding shares.
• The largest buyers of Sarepta Therapeutics for the quarter ending December 2025 were VANGUARD PORTFOLIO MANAGEMENT LLC (6.64Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.58Mn), RA CAPITAL MANAGEMENT, L.P. (3.9Mn), TWO SIGMA INVESTMENTS, LP (2.15Mn), FIRST TRUST ADVISORS LP (2.14Mn).
• The largest sales of SRPT for the quarter ending December 2025 came from AQR CAPITAL MANAGEMENT LLC (1.36Mn), D. E. Shaw & Co., Inc. (1.07Mn), VOLORIDGE INVESTMENT MANAGEMENT, LLC (445.86K), NATIONAL BANK OF CANADA /FI/ (222.89K), Aquatic Capital Management LLC (194.61K).
• Per Business Quant, the top 10 investors in SRPT for the quarter ending December 2025 include BlackRock, Inc. (14.76Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (6.64Mn), State Street Corp (6.61Mn), AQR CAPITAL MANAGEMENT LLC (6.43Mn), TWO SIGMA INVESTMENTS, LP (4.59Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.58Mn), FIRST TRUST ADVISORS LP (4.14Mn), RA CAPITAL MANAGEMENT, L.P. (3.9Mn), Erste Asset Management GmbH (2.97Mn), Morgan Stanley (2.6Mn).